A Phase 1 Multicenter Open-label Dose-Exploration and Dose-Expansion Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Triple Negative Breast Cancer subjects only: Subject must have histologically or cytologically confirmed metastatic or locally recurrent ER-negative (< 1% by IHC), PR-negative (< 1% by IHC), and Her2-negative (either FISH negative, 0 or 1+ by IHC, or IHC2+ and FISH negative per ASCO/CAP definition) breast cancer. Subject must be relapsed/refractory to at least one line of systemic chemotherapy in the metastatic setting or intolerant of existing therapy(ies) known to provide clinical benefit for their condition. Prior exposure to an immune checkpoint inhibitor is allowed. TP53MUT testing is not required.

You may not be eligible for this study if the following are true:

  • 1) Active brain metastases. 2) More than 3 prior lines of chemotherapy in metastatic setting. 3) Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or cardiac arrhythmia requiring medication.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.